Changes in cardiac output and incidence of volume overload in cirrhotics receiving 20% albumin infusion.
Saggere M Shasthry, Manoj Kumar, Jelen S Khumuckham...
https://pubmed.ncbi.nlm.nih.gov/28135785Actively Recruiting
Age: 18Years +
All Genders
Healthy Volunteers
ID06556914
Effect of Albumin Replacement on Oxygen Delivery in Sepsis Patients
Led by Samsun University · Updated on 2025-07-03
45
Participants Needed
1
Research Sites
2 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying the effect of albumin replacement on oxygen delivery in patients with sepsis admitted to the intensive care unit. Sepsis treatment involves fluid resuscitation to improve cardiac output and oxygen delivery, with current guidelines recommending balanced crystalloids as first-line therapy. This study aims to explore how albumin infusion influences oxygen delivery, a factor not yet evaluated in sepsis care. Patients over 18 years old diagnosed with sepsis and hypo-albuminemia after receiving more than 4 liters of crystalloid fluids per day will receive albumin replacement. The treatment includes administering 100 mL of 20% albumin intravenously over at least 15 minutes once daily for three days. Alongside albumin, patients receive standard sepsis care including antibiotics, fluid infusion, norepinephrine to maintain blood pressure, and infection control as per guidelines. Participants will be closely monitored with evaluations including echocardiography, blood gas tests, and calculation of oxygen delivery six times over three days. The severity of illness is assessed using the SOFA score once daily for three days. Researchers will track fluid intake and output, blood parameters, and organ function to understand the impact of albumin on patient outcomes. The primary outcome is oxygen delivery measured up to one hour after albumin infusion, with changes in SOFA score also assessed during the study period.
CONDITIONS
Brief Title
Effect of Albumin Replacement on Oxygen Delivery in Sepsis Patients
Who Can Participate
Age: 18Years +
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Followed up with a diagnosis of sepsis
- Over 18 years old
- Diagnosed with hypo-albuminemia after receiving more than 4 liters of fluid resuscitation per day and underwent albumin replacement
You will not qualify if you...
- Consent is not given by the patient or guardian
- Initial cause of shock was hypovolemic, cardiogenic, or obstructive shock
- Pregnancy or suspected pregnancy
- Peripheral limb or severe organ ischemia due to peripheral artery disease
- Cardiac functions cannot be evaluated optimally by transthoracic echocardiography
- Patients who died within the first 24 hours after intensive care admission
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Monitoring
Duration - 3 days
Participants are observed in the intensive care unit with sepsis and hypo-albuminemia, receiving standard treatment and albumin replacement as needed.
Daily assessments during albumin replacement
Trial Site Locations
Total: 1 location
1
Samsun University
Samsun, Ilkadım, Turkey (Türkiye), 55100
Actively Recruiting
Loading map...
Research Team
G
gamze MD ertaş, specialist
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here